Comparison of Cardiovascular Outcomes of Pioglitazone and Metformin in Type 2 Diabetes Patients

• Status: Withdrawn
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The study aims to see if there is any significant difference in the cardiovascular outcomes in type 2 diabetes patients who are treated with pioglitazone or Metformin

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Postgraduate Institute of Medical Education and Research
• Collaborator: Council of Scientific and Industrial Research, India
• Treatments: Metformin; Pioglitazone

Criteria

Inclusion Criteria:

1. Newly diagnosed (less than six months since diagnosis and not controlled on dietary modifications) type 2 diabetic patients of both sexes aged 25-60 years.

2. Ready to give written informed consent

Exclusion Criteria:

1. Presence of ketonuria

2. Severe concurrent, infection or illness

3. History of hypersensitivity to any study drug

4. Impaired renal function

5. Pulmonary insufficiency with hypoxemia

6. Severe hepatic disease

7. Congestive heart failure

8. History of myocardial infarction or angina(stable/unstable)

9. History of alcohol or drug abuse

10. Pregnant or lactating women -